Anzeige
Mehr »
Login
Freitag, 14.02.2025 Börsentäglich über 12.000 News von 685 internationalen Medien
Dieser unterschätzte Rohstoff hat explosives Potenzial! Hebeln Sie dieses noch mit dieser Aktie!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2JLT3 | ISIN: SE0011205202 | Ticker-Symbol: VTFN
Tradegate
13.02.25
17:04 Uhr
18,190 Euro
+0,010
+0,06 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
VITROLIFE AB Chart 1 Jahr
5-Tage-Chart
VITROLIFE AB 5-Tage-Chart
RealtimeGeldBriefZeit
18,12018,40008:22
18,17018,34008:21
PR Newswire
310 Leser
Artikel bewerten:
(2)

Vitrolife AB (publ) interim report Q2, 2024: Strong Technologies growth and improved margins

Finanznachrichten News

GOTHENBURG, Sweden, July 17, 2024 /PRNewswire/ --

Second quarter

  • Sales of SEK 941 (905) million, an increase of 4% in local currencies and 4% in SEK.
  • Sales per region, in local currencies was -5% in APAC, +11% in EMEA and +5% in Americas.
  • Sales growth per business area, in local currencies, was +3% in Consumables, +40% in Technologies and -7% in Genetics.
  • Gross margin increased to 59.9% (55.8).
  • Operating income before depreciation and amortisation (EBITDA) increased to SEK 327 (293) million, giving an EBITDA margin of 34.7% (32.4).
  • Operating cash flow increased to SEK 236 million (211).
  • Net income increased to SEK 143 (106) million, giving earnings per share of SEK 1.06 (0.78).
  • Vitrolife Group acquired the distribution activities of medical devices from EMB, our Iberian distributor.
  • Vitrolife Group acquired eFertility (STB Zorg B.V.).

First half year

  • Sales of SEK 1,782 (1,759) million, an increase of 2% in local currencies and 1% in SEK.
  • Sales per region, in local currencies was +6% in APAC, +4% in EMEA and -4% in Americas.
  • Sales per business area, in local currencies was +8% in Consumables, +23% in Technologies and -10% in Genetics.
  • Gross margin increased to 58.6% (56.3).
  • Operating income before depreciation and amortisation (EBITDA) increased to SEK 600 (554) million, giving an EBITDA margin of 33.6% (31.5).
  • Operating cash flow increased to SEK 434 million (372).
  • Net income increased to SEK 258 (205) million, giving earnings per share of SEK 1.91 (1.52).

Gothenburg, July 17, 2024
VITROLIFE AB (publ)
Bronwyn Brophy O'Connor, CEO

This disclosure contains information that Vitrolife AB (publ) is obliged to make public pursuant to the Swedish Securities Markets Act (2007:528). The information was submitted for publication, through the agency of the contact person, on 17-07-2024 08:00 CET.

Contact:
Patrik Tolf, CFO, phone +46 (0) 31 766 90 21

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/vitrolife-ab--publ-/r/interim-report-q2--2024--strong-technologies-growth-and-improved-margins,c4015708

The following files are available for download:

https://mb.cision.com/Main/1031/4015708/2918602.pdf

Interim report Q2, 2024

SOURCE Vitrolife AB (publ)

© 2024 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.